HomeONCY • NASDAQ
Oncolytics Biotech Inc
add
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (CAD) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 5.71M | -27.95% |
Net income | -6.17M | 15.04% |
Net profit margin | — | — |
Earnings per share | -0.07 | 28.86% |
EBITDA | -5.68M | 28.02% |
Effective tax rate | -1.40% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (CAD) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 14.63M | -41.14% |
Total assets | 19.97M | -37.72% |
Total liabilities | 13.89M | 0.92% |
Total equity | 6.09M | — |
Shares outstanding | 88.07M | — |
Price to book | 12.29 | — |
Return on assets | -71.91% | — |
Return on capital | -197.15% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (CAD) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | -6.17M | 15.04% |
Cash from operations | -5.47M | 19.77% |
Cash from investing | — | — |
Cash from financing | 5.37M | 172.05% |
Net change in cash | -677.00K | 85.76% |
Free cash flow | -3.77M | 16.55% |
Previous close
$0.86
Day range
$0.86 - $1.06
Year range
$0.33 - $1.53
Market cap
92.57M USD
Avg Volume
1.25M
P/E ratio
-
Dividend yield
-
About
Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. Wikipedia
Founded
1998
Headquarters
Website
Employees
28
